Black Hawk Acquisition Corp
corporate_fare Company Profile
Black Hawk Acquisition Corp (NASDAQ:BKHA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for BKHA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-23, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for BKHA spans 8-K, 10-Q, 425, 424B4.
Recent high-impact activity:
- Black Hawk Pays $150,000 to Push Vesicor Merger Deadline to November 22
- Black Hawk Shareholders Approve Vesicor Merger; 2.09M Shares Redeemed for $25.2M
- Black Hawk Q3 Shows $1.07M Net Income From Debt Forgiveness, But Going Concern Warning Persists
- Black Hawk Discloses Full Meteora Financing Terms: $200M Equity Line, Forward Purchase, and Non-Redemption Backstop
- Black Hawk Secures $200M Equity Line and Backstop Financing with Meteora
Financial Snapshot
Short Interest & Short Volume
2.01 days to coverFINRA reported short interest of 103,214 shares in BKHA as of the October 15, 2026 settlement, a 20501.6% increase from the prior period — about 2.0 days to cover at its recent average daily volume. On October 29, 2026, 36.4% of BKHA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for BKHA, detected from its recent SEC filings · based on capital-structure filings through 2026-09-24.
$200M Standby Equity Purchase Agreement · Convertible Notes with Aggressive Terms
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →